MACROMOLECULAR CRYSTALLOGRAPHY OF THERAPEUTIC PROTEIN COMPLEXES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 VITAE制药公司是一家以结构为基础的药物设计公司，它采取机会主义的方法来选择目标，我们认为我们可以在开发新的治疗剂以满足未得到满足的医疗需求方面产生重大影响。我们追求的所有目标都经过了制药行业的实验和临床验证，许多目标都有结构数据可用来启动基于结构的计划。然后在内部投入大量精力来开发所需的实验结构生物学，以指导药物化学并验证相关建模和计算工作的结果。这种方法已经成功地应用于我们的肾素高血压项目。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vitae Pharmaceuticals is a structure-based, drug design company that takes an opportunistic approach to target selection where we feel we can have a significant impact in developing novel therapeutic agents to meet un-met medical needs. All of the targets that we pursue have been experimentally and clinically validated by the pharmaceutical industry and many have structural data available to initiate a structure-based program. Significant effort is then devoted internally to develop the required experimental structural biology to guide medicinal chemistry and validate the results of the associated modeling and computational efforts. This approach has been successfully applied to our renin hypertension program.